Short communication: Prevalence of long-acting injectable antipsychotic use in Canadian early intervention services for psychosis

Abdel-Baki, 2020, Impact of early use of long-acting injectable antipsychotics on psychotic relapses and hospitalizations in first-episode psychosis, Int. Clin. Psychopharmacol., 35, 221, 10.1097/YIC.0000000000000310 Agid, 2010, Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention, Expet Opin. Pharmacother., 11, 2301, 10.1517/14656566.2010.499125 Barnes, 2003, The barnes akathisia rating scale–revisited, J. Psychopharmacol., 17, 365, 10.1177/0269881103174013 Barnes, 2009, Antipsychotic long-acting injections: prescribing practice in the UK, Br. J. Psychiatr. Suppl., 195, s37, 10.1192/bjp.195.52.s37 Bartoli, 2022, Effect of long-acting injectable antipsychotics on 1-year hospitalization in bipolar disorder: a mirror-image study, Eur. Arch. Psychiatr. Clin. Neurosci., 1 Bartoli, 2022, Comparing 1-year effectiveness and acceptability of once-monthly paliperidone palmitate and aripiprazole monohydrate for schizophrenia spectrum disorders: findings from the STAR Network Depot Study, Psychiatr. Res., 309, 10.1016/j.psychres.2022.114405 Bioque, 2020, Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: a retrospective 6-month mirror-image study, Eur. Psychiatr., 63, 1, 10.1192/j.eurpsy.2020.72 Brodeur, 2022, Antipsychotic utilization trajectories three years after initiating or reinitiating treatment of schizophrenia: a state sequence analysis approach, Acta Psychiatr. Scand., 145, 469, 10.1111/acps.13411 Brodeur, 2022, Comparative effectiveness and safety of antipsychotic drugs in patients with schizophrenia initiating or reinitiating treatment: a Real‐World Observational Study, Acta Psychiatr. Scand., 145, 456, 10.1111/acps.13413 Chouinard, 2005, Manual for the extrapyramidal symptom rating scale (ESRS), Schizophr. Res., 76, 247, 10.1016/j.schres.2005.02.013 Fefeu, 2018, One-year mirror-image study of the impact of olanzapine long-acting injection on healthcare resource utilization and costs in severe schizophrenia, Psychiatr. Res., 270, 205, 10.1016/j.psychres.2018.09.041 Guy, 1976 Haro, 2003, The Clinical Global Impression–Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia, Acta Psychiatr. Scand., 107, 16, 10.1034/j.1600-0447.107.s416.5.x Hastings, T. (n.d.). Tool for monitoring antipsychotic side effects (TMAS) [WWW Document]. URL 10.31.22 https://www.epicanada.org/tmas. Iyer, 2013, A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: Part I—patient perspectives, Crim. Justice Pol. Rev., 58, 14 Iyer, 2013, A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: Part II—physician perspectives, Crim. Justice Pol. Rev., 58, 23 Jablensky, 2000, Psychotic disorders in urban areas: an overview of the study on low prevalence disorders, Aust Nz J Psychiat, 34, 221, 10.1080/j.1440-1614.2000.00728.x Kane, 2020, Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia, Jama Psychiat, 77, 1217, 10.1001/jamapsychiatry.2020.2076 Kishi, 2021, Association between discontinuation due to withdrawal of consent and use of long-acting injectable antipsychotics: a meta-analysis of randomized trials for schizophrenia, J. Psychiatr. Res., 132, 144, 10.1016/j.jpsychires.2020.10.009 Kishimoto, 2021, Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies, Lancet Psychiatr., 8, 387, 10.1016/S2215-0366(21)00039-0 Lian, 2022, Efficacy of long‐acting injectable versus oral antipsychotic drugs in early psychosis: a systematic review and meta‐analysis, Early Interv Psychia, 16, 589, 10.1111/eip.13202 Lin, 2021, Real-world evidence of the clinical and economic impact of long-acting injectable versus oral antipsychotics among patients with schizophrenia in the United States: a systematic review and meta-analysis, CNS Drugs, 35, 469, 10.1007/s40263-021-00815-y Mahlich, 2020, Hospitalization rates and therapy costs of German schizophrenia patients who are initiated on long-acting injectable medication: a mirror-image study, Clin. Drug Invest., 40, 355, 10.1007/s40261-020-00900-y Malla, 2013, Long-acting injectable antipsychotics: recommendations for clinicians, CanJPsychiatry, 58, 30 Manchanda, 2013, Long-acting injectable antipsychotics: evidence of effectiveness and use, Crim. Justice Pol. Rev., 58, 5 McKee, 2021, Long-acting injectable antipsychotic (LAI) prescribing trends during COVID-19 restrictions in Canada: a retrospective observational study, BMC Psychiatr., 21, 633, 10.1186/s12888-021-03646-9 Miura, 2019, Long-acting injectables versus oral antipsychotics: a retrospective bidirectional mirror-image study, J. Clin. Psychopharmacol., 39, 441, 10.1097/JCP.0000000000001082 Mond, 2003, Use of antipsychotic medications in Australia between july 1995 and december 2001, Aust. N. Z. J. Psychiatr., 37, 55, 10.1046/j.1440-1614.2003.01110.x Nolin, 2016, Early intervention for psychosis in Canada, Can. J. Psychiatr., 61, 186, 10.1177/0706743716632516 Olagunju, 2019, Long-acting atypical antipsychotics in schizophrenia: a systematic review and meta-analyses of effects on functional outcome, Aust. N. Z. J. Psychiatr., 53, 509, 10.1177/0004867419837358 Ostuzzi, 2021, Maintenance treatment with long-acting injectable antipsychotics for people with nonaffective psychoses: a network meta-analysis, Am. J. Psychiatr., 178, 424, 10.1176/appi.ajp.2020.20071120 Ostuzzi, 2023, Clinical trajectories of individuals with severe mental illness continuing and discontinuing long-acting antipsychotics: a one-year mirror-image analysis from the STAR Network Depot study, Schizophrenia, 9, 23, 10.1038/s41537-023-00342-3 Pappa, 2020, Partial compliance with long-acting paliperidone palmitate and impact on hospitalization: a 6-year mirror-image study, Ther Adv Psychopharmacol, 10, 10.1177/2045125320924789 Parellada, 2016, Barriers to the use of long-acting injectable antipsychotics in the management of schizophrenia, CNS Drugs, 30, 689, 10.1007/s40263-016-0350-7 Park, 2018, Comparative efficacy and safety of long-acting injectable and oral second-generation antipsychotics for the treatment of schizophrenia: a systematic review and meta-analysis, Clin Psychopharm Neu, 16, 361 Robinson, 2002, Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder, Schizophr. Res., 57, 209, 10.1016/S0920-9964(01)00312-7 Roy, 2020, The evolution of long-acting antipsychotics use in Québec between 2003 and 2017, Can. J. Psychiatr., 65, 510, 10.1177/0706743720901975 Stip, 2011, Les antipsychotiques injectables à action prolongée: avis d’experts de l'Association des médecins psychiatres du Québec, Can. J. Psychiatr., 56, 367, 10.1177/070674371105600608 Stip, 2019, Antipsychotiques à Action Prolongée: Révision de l’algorithme QAAPAPLE, Can. J. Psychiatr., 64, 697 Taipale, 2018, Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia, Schizophr. Res., 197, 274, 10.1016/j.schres.2017.12.010 Takács, 2019, Comparative effectiveness of second generation long-acting injectable antipsychotics based on nationwide database research in Hungary, PLoS One, 14, 10.1371/journal.pone.0218071 Uribe, 2020, Preliminary efficacy and tolerability profiles of first versus second-generation Long-Acting Injectable Antipsychotics in schizophrenia: a systematic review and meta-analysis, J. Psychiatr. Res., 129, 222, 10.1016/j.jpsychires.2020.06.013 Verdoux, 2016, Antipsychotic long-acting injections: a community-based study from 2007 to 2014 of prescribing trends and characteristics associated with initiation, Schizophr. Res., 178, 58, 10.1016/j.schres.2016.09.014 Weiden, 2013, Why are Canadians complacent about long-acting injectable antipsychotic therapies? Come on, Canada, you can do better, Can. J. Psychiatr., 58, 3S, 10.1177/088740341305805s01 Williams, 2006, Medication decisions and clinical outcomes in the Canadian national outcomes measurement study in schizophrenia, Acta Psychiatr. Scand., 113, 12, 10.1111/j.1600-0447.2006.00757.x Wu, 2016, Comparison of treatment effectiveness and medical costs for different long-acting injectable antipsychotics in patients with schizophrenia in Taiwan: a nationwide population-based cohort study, Schizophr. Res., 173, 37, 10.1016/j.schres.2016.02.037 Xiang, 2008, Clinical and social correlates with the use of depot antipsychotic drugs in outpatients with schizophrenia in China, Int. J. Clin. Pharm. Ther., 46, 245, 10.5414/CPP46245